Key result
Mechanistic iron-deficiency phenotypes show no link to 1-year death or worsening HF after IV iron.
Why the study?
Although intravenous iron is recommended for HF with iron deficiency, the clinical relevance of three mechanistic iron-deficiency phenotypes and the prognostic value of the change in transferrin saturation after ferric carboxymaltose therapy are unknown.
Does classification into mechanistic iron-deficiency phenotypes (Types 1–3) or change in transferrin saturation (ΔTSAT) predict the 1-year composite of all-cause death, heart failure hospitalization, or emergency department visit for worsening heart failure in patients with chronic heart failure treated with intravenous ferric carboxymaltose?
Cohort (n=146)
No
Does classification into mechanistic iron-deficiency phenotypes (Types 1–3) or change in transferrin saturation (ΔTSAT) predict the 1-year composite of all-cause death, heart failure hospitalization, or emergency department visit for worsening heart failure in patients with chronic heart failure treated with intravenous ferric carboxymaltose?
Answers are grounded in this paper and cite their sources.
In patients with chronic heart failure receiving intravenous ferric carboxymaltose, operationally defined mechanistic iron-deficiency phenotypes (Types 1–3) and baseline iron biomarkers showed poor discrimination and were not significantly associated with 1-year clinical outcomes, though marked hypoferremia (Type 1, TSAT ≤16%) showed a directional signal toward higher risk over longer follow-up.
Objective Intravenous iron is recommended for heart failure (HF) with iron deficiency. A recent framework describes three mechanistic iron-deficiency phenotypes, but their clinical relevance and the prognostic value of the change in transferrin saturation (ΔTSAT) after intravenous iron are unknown. We examined both in patients treated with ferric carboxymaltose (FCM). Methods In this retrospective single-center cohort, 146 patients with chronic HF received a single 1,000 mg dose of FCM and were classified into non-mutually exclusive, study-defined Type 1–3 phenotypes. The primary outcome was a composite of all-cause death, HF hospitalization, or emergency department visit for worsening HF within 1 year. Associations were estimated with logistic regression adjusted for age, sex, left ventricular ejection fraction, NYHA class, and anemia, with sensitivity analyses including Cox regression over the protocol-defined follow-up (to 1 year after the post-treatment TSAT measurement). ΔTSAT analyses were exploratory. Results The composite outcome occurred in 32 patients (21.9%). No phenotype was significantly associated with the outcome: Type 1 (adjusted odds ratio [OR] 2.60, 95% confidence interval [CI] 0.84–8.01), Type 2 (OR 0.40, 95% CI 0.11–1.42), and Type 3 (OR 0.66, 95% CI 0.21–2.11); NYHA class III–IV showed a borderline association (OR 3.41, 95% CI 0.95–12.18). Over the longer protocol-defined follow-up (40 events), the hazard ratio for Type 1 was 2.99 (95% CI 1.19–7.51). Among 139 patients with post-treatment TSAT, ΔTSAT was not associated with the outcome (adjusted OR per 10-point increase 1.00, 95% CI 0.80–1.24), with no effect modification by phenotype (global p = 0.37); however, in 22 of 27 patients with an event, the event preceded the post-treatment measurement. Discrimination (area under the receiver operating characteristic curve) was poor for baseline TSAT (0.57), ΔTSAT (0.50), and ferritin (0.44). Conclusion Operationally defined phenotypes were not significantly associated with the 1-year composite outcome; marked hypoferremia (Type 1) demonstrated a consistent directional signal across analyses, although estimates were imprecise and require prospective validation. Because most events preceded the post-treatment TSAT measurement, the prognostic value of the TSAT response could not be assessed. The present results should be considered exploratory owing to limited sample size and event rates.
No takes yet. Share an insight, caveat, or question.
Kaya et al. (2026) conducted a cohort in Chronic heart failure with iron deficiency (n=146). Type 1 iron deficiency phenotype (marked systemic hypoferremia, baseline TSAT ≤16%) vs. Patients not meeting Type 1, Type 2, or Type 3 mechanistic iron-deficiency phenotype criteria ( adjusted for overlapping phenotypes) was evaluated on Composite of all-cause death, hospitalization for worsening heart failure, or emergency department visit for worsening heart failure within 1 year (OR 2.60, 95% CI 0.84-8.01, p=0.096). Mechanistic iron-deficiency phenotypes (Types 1-3) were not associated with 1-year death or worsening HF events after IV iron.
Synapse has enriched 10 related papers. Consider them for comparative context: